// App-Quantinova.ai

Tu1135 : Serum Adalimumab and Immunogenicity in IBD Patients After 80mg Biweekly Maintenance Therapy

Researchers

Presenter

  • Scott Hauenstein

Principal Investigators

  • Anna Iacono

  • Sue P. Irwin

  • Sharat Singh

  • Gordon R. Greenberg

Medical Centers

  • Department of Surgery, University of Toronto, Toronto, ON, Canada

  • Division of Gastroenterology, Mount Sinai Hospital, Toronto, Ontario, Canada

Locations

  • Canada

Companies

  • Prometheus Laborator

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Inflammatory bowel disease

  • Ulcerative colitis

Biomarkers

  • C reactive protein

Drug/Treatment

  • Adalimumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved